Ulcerative Colitis

Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis
Pfizer's Ulcerative Colitis Candidate Aces Late-Stage Study
Janssen's Tremfya Shows Clinical Response At 12 Weeks In Ulcerative Colitis
Pfizer's Ulcerative Colitis Candidate Aces Late-Stage Study
Janssen's Tremfya Shows Clinical Response At 12 Weeks In Ulcerative Colitis
Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study
Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Ulcerative Colitis Recent News

Ventyx Jumps Over 20% Today After NASDAQ Debut
Less than a year ago, Ventyx Biosciences Inc (NASDAQ: VTYX) emerged from stealth mode, then last month, it sprinted to Wall Street with a $100 million IPO ticket.
Bristol Myers' TYK2 Inhibitor Disappoints In Mid-Stage Ulcerative Colitis Study
Why Did Kaleido Shares Plunge 10% On Tuesday?
Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients
Eli Lilly's Mirikizumab Maintains Symptomatic Remission for Two Years In Ulcerative Colitis Patients
Eli Lilly And Co (NYSE: LLY) has posted new data from the Phase 2 study of mirikizumab in moderately to severely active ulcerative colitis (UC) patients.
AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis
Analysts Slash Price Targets After Theravance's Failed Ulcerative Colitis Study
Analysts have lowered the price target and downgraded Theravance Biopharma Inc (NASDAQ: TBPH) after disappointing ulcerative colitis Phase 2 trial data.
Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study
Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study
Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). 
Galapagos Shares Drop As SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis Patients
Johnson & Johnson Posts Positive 3-Year Stelara Data In Ulcerative Colitis
Eli Lilly's Mirikizumab Shows Mucosal Healing In Ulcerative Colitis Maintained For Up To One Year
Bristol-Myers' Zeposia Scores FDA Approval For Ulcerative Colitis
Progenity's Targeted Delivery Of Adalimumab Shows Encouraging Action In Animal Models Induced With Colitis
Bristol Myers Unveils More Positive Data On Ulcerative Colitis Candidate Zeposia
Eli Lil­ly Aban­dons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications
I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study
Eli Lilly's Mirikizumab Beat Placebo At Controlling, Resolving Ulcerative Colitis Symptoms
Eli Lilly and Co's (NYSE: LLY) Mirikizumab is now one step closer to get approval after 
AbbVie's Humira Gets FDA Approval For Pediatric Ulcerative Colitis
AbbVie's Upadacitinib Shows Clinical Benefit In Second Late-Stage Ulcerative Colitis Study
Here's Why Arena Pharmaceuticals Jumped 30% Tuesday
Immune Pharmaceuticals CEO Talks Company And Its Recent Market Rally